Multicancer Detection (MCD) Testing in Gastrointestinal Cancers: An Evolving Tool for Early Diagnosis

Area of Science:

• Oncology
• Biomarker Discovery
• Medical Diagnostics

Background:

• Gastrointestinal (GI) cancer screening often involves invasive methods with limited sensitivity.
• Effective screening options are lacking for several GI malignancies, including pancreatic and liver cancers.
• Multicancer detection (MCD) tests represent a novel approach to cancer diagnostics.

Purpose of the Study:

• To review the benefits and limitations of multicancer detection (MCD) tests for diagnosing GI malignancies.
• To evaluate the potential of MCD tests as a non-invasive screening tool.
• To discuss the current challenges and future directions for MCD implementation in clinical practice.

Main Methods:

• Literature review of studies on multicancer detection tests for GI cancers.
• Analysis of biomarker detection methods, including cell-free DNA and RNA.
• Evaluation of machine learning applications in cancer signal identification.

Main Results:

• MCD tests show promise as non-invasive alternatives, utilizing biomarkers like cell-free DNA.
• Studies demonstrate feasibility and accuracy, particularly for GI cancers lacking routine screening (e.g., pancreas, liver).
• Challenges include high costs, absence of FDA approval, potential for false positives, and limited data on mortality reduction.

Conclusions:

• MCD tests can augment traditional screening, especially for unscreened cancers like cholangiocarcinoma and pancreatic cancer.
• MCD should not replace existing age-appropriate screenings but can complement them.
• Further research is crucial to establish clinical utility, address limitations, and guide shared decision-making with patients.